Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 391 to 405 of 563 results for oral care

  1. For people with iron-deficiency anaemia, how long before surgery should oral iron supplementation be started, and what is the clinical and cost effectiveness of daily oral iron compared with oral iron given on alternate days?

    surgery should oral iron supplementation be started, and what is the clinical and cost effectiveness of daily oral iron...

  2. Good practice guidance – Interim process statement (PMG3)

    This interim process statement has been produced to guide the development of good practice guidance. It provides an overview of the key process principles and describes all stages of the development of good practice guidance

  3. Harmful sexual behaviour among children and young people (NG55)

    This guideline covers children and young people who display harmful sexual behaviour, including those on remand or serving community or custodial sentences. It aims to ensure these problems don’t escalate and possibly lead to them being charged with a sexual offence. It also aims to ensure no-one is unnecessarily referred to specialist services.

  4. Flu vaccination: increasing uptake (NG103)

    This guideline covers how to increase uptake of the free flu vaccination among people who are eligible. It describes ways to increase awareness and how to use all opportunities in primary and secondary care to identify people who should be encouraged to have the vaccination.

  5. Idelalisib for treating refractory follicular lymphoma (TA604)

    Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.

  6. Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)

    Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.

  7. Indicator advisory committee members

    Read biographies for all members of NICE's indicator advisory committee.

  8. Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)

    Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making

  9. Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)

    Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.

  10. What local anaesthetic techniques are most effective for women having surgical abortion?

    need to minimise their recovery time (if they are driving home, or if they care for dependents) some women are anxious about the...

  11. Secukinumab for treating moderate to severe plaque psoriasis (TA350)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating plaque psoriasis in adults.

  12. The Insides System for managing intestinal failure (MIB286)

    NICE has developed a medtech innovation briefing (MIB) on The Insides System for managing intestinal failure .

  13. Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333)

    Evidence-based recommendations on axitinib (Inlyta) for previously treated advanced renal cell carcinoma in adults.

  14. Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)

    Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs.

  15. Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)

    Evidence-based recommendations on ponatinib (Iclusig) for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia in adults.